SynAct Pharma AB
STO:SYNACT
Operating Margin
SynAct Pharma AB
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
SE |
S
|
SynAct Pharma AB
STO:SYNACT
|
978.2m SEK | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
337.9B USD |
30%
|
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
165.8B USD |
25%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
141.4B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
130.4B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.9B USD |
29%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
SynAct Pharma AB
Glance View
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on SynAct Pharma AB's most recent financial statements, the company has Operating Margin of 0%.